Top

Breast Cancer Research and Treatment

Published in:

01-06-2019 | Metastasis | Review

The next generation personalized models to screen hidden layers of breast cancer tumorigenicity

Authors: F. Afzali, P. Akbari, H. Naderi-Manesh, M. Gardaneh

Published in: Breast Cancer Research and Treatment | Issue 2/2019

Abstract

Background

Breast cancer (BC) is a challenging disease and major cause of death amongst women worldwide who die due to tumor relapse or sidelong diseases. BC main complexity comes from the heterogeneous nature of breast tumors that demands customized treatments in the form of personalized medicine.

Review of the literature and discussion

Spatiotemporally dynamic and heterogeneous nature of BC tumors is shaped by their clonal evolution and sub-clonal selections and shapes resistance to collective or group therapies that drives cancer recurrence and tumor metastasis. Personalized intervention promises to administer medications that selectively target each individual patient tumor and even further each colonized secondary tumor. Such personalized regimens will require creation of in vitro and in vivo models genuinely recapitulating characteristics of each tumor type as initiating platforms for two main purposes: to closely monitor the tumorigenic processes that shape tumor heterogeneity and evolution as the main driving forces behind tumor chemo-resistance and relapse, and subsequently to establish patient-specific preventive and therapeutic measures. While application of tumor modeling for personalized drug screening and design requires a separate review, here we discuss the personalized utilities of xenograft modeling in investigating BC tumor formation and progression toward metastasis. We will further elaborate on the impact of innovative technologies on personalized modeling of BC tumorigenicity at improved resolution.

Conclusion

Heterogeneous nature of each BC tumor requires personalized intervention implying that modeling breast tumors is inevitable for better disease understanding, detection and cure. Patient-derived xenografts are just the initiating piece of the puzzle for ideal management of breast cancer. Emerging technologies promise to model BC more personalized than before.

Huxley J (1958) The biological aspects of cancer. Harcourt, Brace, New York

McGranahan N, Swanton C (2017) Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 168(4):613–628. https://doi.org/10.1016/j.cell.2017.01.018 CrossRefPubMed

De Bruin EC, McGranahan N, Mitter R et al (2014) Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346(6206):251–256. https://doi.org/10.1126/science.1253462 CrossRefPubMedPubMedCentral

Mazor T, Pankov A, Song JS et al (2016) Intratumoral heterogeneity of the epigenome. Cancer Cell 29(4):440–451. https://doi.org/10.1016/j.ccell.2016.03.009 CrossRefPubMedPubMedCentral

Martinez P, Birkbak NJ, Gerlinger M et al (2013) Parallel evolution of tumoursubclones mimics diversity between tumours. J Pathol 230(4):356–364. https://doi.org/10.1002/path.4214 CrossRefPubMed

Bombonati A, Sgroi DC (2011) The molecular pathology of breast cancer progression. J Pathol 223(2):308–318. https://doi.org/10.1002/path.2808 CrossRef

Polyak K (2007) Breast cancer: origins and evolution. J Clin Invest 117(11):3155–3163. https://doi.org/10.1172/JCI33295 CrossRefPubMedPubMedCentral

Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61. https://doi.org/10.1038/nature11412 CrossRef

Curtis C, Shah SP, Chin SF et al (2012) The genomic and transcriptomic architecture of 2,000 breast tumoursreveals novel subgroups. Nature 486(7403):346. https://doi.org/10.1038/nature10983 CrossRefPubMedPubMedCentral

10.

Ali HR, Rueda OM, Chin SF et al (2014) Genome-driven integrated classification of breast cancer validated in over 7,500 samples. Genome Biol 15(8):431. https://doi.org/10.1186/s13059-014-0431-1 CrossRefPubMedPubMedCentral

11.

Malaney P, Nicosia SV, Davé V (2014) One mouse, one patient paradigm: New avatars of personalized cancer therapy. Cancer Lett 344(1):1–2. https://doi.org/10.1016/j.canlet.2013.10.010 CrossRefPubMed

12.

Morton CL, Houghton PJ (2007) Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc 2(2):247. https://doi.org/10.1038/nprot.2007.25 CrossRefPubMed

13.

Jin K, Teng L, Shen Y et al (2010) Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review. Clin Transl Oncol 12(7):473–480. https://doi.org/10.1007/s12094-010-0540-6 CrossRefPubMed

14.

Cheon DJ, Orsulic S (2011) Mouse models of cancer. Annu Rev Pathol-Mech 6:95–119. https://doi.org/10.1146/annurev.pathol.3.121806.154244 CrossRef

15.

Kersten K, de Visser KE, van Miltenburg MH et al (2016) Genetically engineered mouse models in oncology research and cancer medicine. EMBO Mol Med 9(2):137–153. https://doi.org/10.15252/emmm.201606857 CrossRefPubMedCentral

16.

Petrillo LA, Wolf DM, Kapoun AM et al (2012) Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors. Breast Cancer Res Treat 135(3):913–922. https://doi.org/10.1007/s10549-012-2226-y CrossRefPubMed

17.

Gardaneh M, Shojaei S, Kaviani A, Behnam B (2017) GDNF induces RET-SRC-HER2-dependent growth in trastuzumab-sensitive but SRC-independent growth in resistant breast tumor cells. Breast Cancer Res Treat 162(2):231–241. https://doi.org/10.1007/s10549-016-4078-3 CrossRefPubMed

18.

Grinde MT, Skrbo N, Moestue SA et al (2014) Interplay of choline metabolites and genes in patient-derived breast cancer xenografts. Breast Cancer Res 16(1):R5. https://doi.org/10.1186/bcr3597 CrossRefPubMedPubMedCentral

19.

Bruna A, Rueda OM, Greenwood W et al (2016) A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anticancer compounds. Cell 167(1):260–274. https://doi.org/10.1016/j.cell.2016.08.041 CrossRefPubMedPubMedCentral

20.

DeRose YS, Wang G, Lin YC et al (2011) Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 17(11):1514–1520. https://doi.org/10.1038/nm.2454 CrossRefPubMedPubMedCentral

21.

Zhang X, Claerhout S, Pratt A et al (2013) A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res 73:4885–4897. https://doi.org/10.1158/0008-5472.CAN-12-4081 CrossRefPubMedPubMedCentral

22.

Ding LI, Ellis MJ, Li S et al (2010) Genome remodeling in a basal-like breast cancer metastasis and xenograft. Nature 464(7291):999. https://doi.org/10.1038/nature08989 CrossRefPubMedPubMedCentral

23.

Nardella C, Lunardi A, Patnaik A et al (2011) The APL paradigm and the “co-clinical trial” project. Cancer Discov 1:108–116. https://doi.org/10.1158/2159-8290.CD-11-0061 CrossRefPubMed

24.

Tentler JJ, Tan AC, Weekes CD et al (2012) Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 9(6):338–350. https://doi.org/10.1038/nrclinonc.2012.61 CrossRefPubMedPubMedCentral

25.

Eirew P, Steif A, Khattra J et al (2015) Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature 518(7539):422–426. https://doi.org/10.1038/nature13952 CrossRefPubMed

26.

Reyal F, Guyader C, Decraene C et al (2012) Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res 14:R11. https://doi.org/10.1186/bcr3095 CrossRefPubMedPubMedCentral

27.

Notta F, Mullighan CG, Wang JC et al (2011) Evolution of human BCR–ABL1 lymphoblastic leukaemia-initiating cells. Nature 469(7330):362–367. https://doi.org/10.1038/nature09733 CrossRefPubMed

28.

Li S, Shen D, Shao J et al (2013) Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Reprod 4(6):1116–1130. https://doi.org/10.1016/j.celrep.2013.08.022 CrossRef

29.

Ben-David U, Ha G, Tseng YY et al (2017) Patient-derived xenografts undergo mouse-specific tumor evolution. Nat Genet 49(11):1567–1575. https://doi.org/10.1038/ng.3967 CrossRefPubMedPubMedCentral

30.

Campbell PJ, Pleasance ED, Stephens PJ et al (2008) Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. Proc Natl Acad Sci USA 105:13081–13086. https://doi.org/10.1073/pnas.0801523105 CrossRefPubMedPubMedCentral

31.

Lawson DA, Bhakta NR, Kessenbrock K et al (2015) Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature 526(7571):131–135. https://doi.org/10.1038/nature15260 CrossRefPubMedPubMedCentral

32.

Yang S, Zhang JJ, Huang XY (2012) Mouse models for tumor metastasis. Methods Mol Biol 928:221–228. https://doi.org/10.1007/978-1-62703-008-3_17 CrossRefPubMedPubMedCentral

33.

Gibson WJ, Hoivik EA, Halle MK et al (2016) The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nat Genet 48(8):848–855. https://doi.org/10.1038/ng.3602 CrossRefPubMedPubMedCentral

34.

Diaz LA Jr., Bardelli A (2014) Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 32(6):579. https://doi.org/10.1200/CO.2012.45.2011 CrossRefPubMedPubMedCentral

35.

Bettegowda C, Sausen M, Leary RJ et al (2014) Detection of circulating tumor DNA in early-and late-stage human malignancies. Sci Transl Med 6(224):224. https://doi.org/10.1126/scitranslmed.3007094 CrossRef

36.

Thierry AR, Mouliere F, El Messaoudi S et al (2014) Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med 20(4):430. https://doi.org/10.1038/nm.3511 CrossRefPubMed

37.

Jamal-Hanjani M, Wilson GA, Horswell S et al (2016) Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer. Ann Oncol 27(5):862–867. https://doi.org/10.1093/annonc/mdw037 CrossRefPubMed

38.

Jamal-Hanjani M, Wilson GA, McGranahan N et al (2017) Tracking the evolution of non–small-cell lung cancer. N Engl J Med 376(22):2109–2121. https://doi.org/10.1056/NEJMoa1616288 CrossRefPubMed

39.

Abbosh C, Birkbak NJ, Wilson GA et al (2017) Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 545(7655):446. https://doi.org/10.1038/nature22364 CrossRefPubMedPubMedCentral

40.

Diaz LA Jr, Williams RT, Wu J et al (2012) The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486(7404):537. https://doi.org/10.1038/nature11219 CrossRefPubMedPubMedCentral

41.

Misale S, Yaeger R, Hobor S et al (2012) Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486(7404):532. https://doi.org/10.1038/nature11156 CrossRefPubMedPubMedCentral

42.

Spoerke JM, Gendreau S, Walter K et al (2016) Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. Nat Commun 7:11579. https://doi.org/10.1038/ncomms11579 CrossRefPubMedPubMedCentral

43.

Murtaza M, Dawson SJ, Tsui DW et al (2013) Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497(7447):108. https://doi.org/10.1038/nature12065 CrossRefPubMed

44.

Leary RJ, Sausen M, Kinde I et al (2012) Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med 4(162):154–162. https://doi.org/10.1126/scitranslmed.3004742 CrossRef

45.

Shoda K, Ichikawa D, Fujita Y et al (2017) Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancer. Gastric Cancer 20(1):126–135. https://doi.org/10.1007/s10120-017-0715-8 CrossRefPubMed

46.

Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, Cheang M, Osin P, Nerurkar A, Kozarewa I, Garrido JA, Dowsett M, Reis-Filho JS, Smith IE, Turner NC (2105) Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med 26(302):302ra133. https://doi.org/10.1126/scitranslmed.aab0021 CrossRef

47.

Yang P, Abo R, Liu Ch, Chen Z, Wu H, Cui J, Yandava Ch, Baily ST, Balch C, Gulcher JR, Chittenden TW (2017) Novel feature selection strategies for enhanced predictive modeling and deep learning in the biosciences [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1–5; Washington DC Philadelphia (PA): AACR; Cancer Res 77(13 Suppl):Abstract nr 4539. https://doi.org/10.1158/1538-7445.AM2017-4539

48.

Caravagna G, Giarratano Y, Ramazzotti D et al (2018) Detecting repeated cancer evolution from multi-region tumor sequencing data. Nat Methods 15(9):707. https://doi.org/10.1038/s41592-018-0108-x CrossRefPubMedPubMedCentral

49.

Way GP, Sanchez-Vega F, La K et al (2018) Machine learning detects pan-cancer Ras pathway activation in the cancer genome atlas. Cell Rep 23:172–180. https://doi.org/10.1016/j.celrep.2018.03.046 CrossRefPubMedPubMedCentral

50.

Li J, Chen L, Zhang YH et al (2018) A computational method for classifying different human tissues with quantitatively tissue-specific expressed genes. Genes 9(9):449. https://doi.org/10.3390/genes9090449 CrossRefPubMedCentral

51.

Zinn PO, Singh SK, Kotrotsou A et al (2018) Validation study: conserved magnetic resonance radiomic appearance of periostin-expressing glioblastoma in patients and xenograft models. Clin Cancer Res 24(24):6288–6299. https://doi.org/10.1158/1078-0432.CCR-17-3420 CrossRefPubMedPubMedCentral

52.

Wang D, Li JR, Zhang YH et al (2018) Identification of differentially expressed genes between original breast cancer and xenograft using machine learning algorithms. Genes 9(3):155. https://doi.org/10.3390/genes9030155 CrossRefPubMedCentral

53.

Jeanquartier F, Jean-Quartier C, Cemernek D et al (2016) In silico modeling for tumor growth visualization. BMC Syst Biol 10(1):59. https://doi.org/10.1186/s12918-016-0318-8 CrossRefPubMedPubMedCentral

54.

Drost J, Clevers H (2018) Organoids in cancer research. Nat Rev Cancer 24:1. https://doi.org/10.1038/s41568-018-0007-6 CrossRef

55.

Vlachogiannis G, Hedayat S, Vatsiou A et al (2018) Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science 359 (6378):920–926. https://doi.org/10.1126/science.aao2774 CrossRefPubMedPubMedCentral

56.

Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK (2017) Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat Rev Cancer 17(4):254. https://doi.org/10.1038/nrc.2016.140 CrossRefPubMed

57.

Wang H, Russa ML, Qi LS (2016) CRISPR/Cas9 in genome editing and beyond. Annu Rev Biochem 85:227–264. https://doi.org/10.1146/annurev-biochem-060815-014607 CrossRefPubMed

58.

Choi PS, Meyerson M (2014) Targeted genomic rearrangements using CRISPR/Cas technology. Nat Commun 5:3728. https://doi.org/10.1038/ncomms4728 CrossRefPubMed

59.

Chen C, Liu Y, Rappaport AR et al (2014) MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia. Cancer Cell 25(5):652–665. https://doi.org/10.1016/j.ccr.2014.03.016 CrossRefPubMedPubMedCentral

60.

Torres R, Martin MC, Garcia A et al (2014) Engineering human tumour-associated chromosomal translocations with the RNA-guided CRISPR–Cas9 system. Nat Commun 5:3964. https://doi.org/10.1038/ncomms4964 CrossRefPubMed

61.

Guernet A, Mungamuri SK, Cartier D et al (2016) CRISPR-barcoding for intratumor genetic heterogeneity modeling and functional analysis of oncogenic driver mutations. Mol Cell 63(3):526–538. https://doi.org/10.1016/j.molcel.2016.06.017 CrossRefPubMedPubMedCentral

62.

Frieda KL, Linton JM, Hormoz S et al (2017) Synthetic recording and in situ readout of lineage information in single cells. Nature 541(7635):107–111. https://doi.org/10.1038/nature20777 CrossRefPubMed

63.

Engelman JA, Chen L, Tan X et al (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14(12):1351. https://doi.org/10.1038/nm.1890 CrossRefPubMedPubMedCentral

64.

Chen Z, Cheng K, Walton Z et al (2012) A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 483(7391):613. https://doi.org/10.1038/nature10937 CrossRefPubMedPubMedCentral

65.

Yang H, Wang H, Shivalila CS et al (2013) One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. Cell 154(6):1370–1379. https://doi.org/10.1016/j.cell.2013.08.022 CrossRefPubMedPubMedCentral

66.

Malina A, Mills JR, Cencic R et al (2013) Repurposing CRISPR/Cas9 for in situ functional assays. Genes Dev 27(23):2602–2614. https://doi.org/10.1101/gad.227132.113 CrossRefPubMedPubMedCentral

67.

Heckl D, Kowalczyk MS, Yudovich D et al (2014) Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Nat Biotechnol 32(9):941. https://doi.org/10.1038/nbt.2951 CrossRefPubMedPubMedCentral

68.

Xue W, Chen S, Yin H et al (2014) CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature 514(7522):380. https://doi.org/10.1038/nature13589 CrossRefPubMedPubMedCentral

69.

Jackson EL, Willis N, Mercer K et al (2001) Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15(24):3243–3248. https://doi.org/10.1101/gad.943001 CrossRefPubMedPubMedCentral

70.

Sánchez-Rivera FJ, Papagiannakopoulos T, Romero R et al (2014) Rapid modelling of cooperating genetic events in cancer through somatic genome editing. Nature 516(7531):428. https://doi.org/10.1038/nature13906 CrossRefPubMedPubMedCentral

71.

Blasco RB, Karaca E, Ambrogio C et al (2014) Simple and rapid in vivo generation of chromosomal rearrangements using CRISPR/Cas9 technology. Cell Rep 9(4):1219–1227. https://doi.org/10.1016/j.celrep.2014.10.051 CrossRefPubMed

72.

Soda M, Choi YL, Enomoto M et al (2007) Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. Nature 448(7153):561. https://doi.org/10.1038/nature05945 CrossRefPubMed

73.

Maddalo D, Manchado E, Concepcion CP et al (2014) In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. Nature 516(7531):423. https://doi.org/10.1038/nature13902 CrossRefPubMedPubMedCentral

74.

Hockemeyer D, Jaenisch R (2016) Induced pluripotent stem cells meet genome editing. Cell Stem Cell 18(5):573–586. https://doi.org/10.1016/j.stem.2016.04.013 CrossRefPubMedPubMedCentral

Title: The next generation personalized models to screen hidden layers of breast cancer tumorigenicity
Authors: F. Afzali
P. Akbari
H. Naderi-Manesh
M. Gardaneh
Publication date: 01-06-2019
Publisher: Springer US
Keywords: Metastasis
Breast Cancer
Artificial Intelligence
Breast Cancer
Published in: Breast Cancer Research and Treatment / Issue 2/2019
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-019-05159-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Review of the literature and discussion

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2019

Screening for distant metastases in patients with ipsilateral breast tumor recurrence: the impact of different imaging modalities on distant recurrence-free interval

A high-risk luminal A dominant breast cancer subtype with increased mobility

Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer

Health-related quality of life in long-term disease-free breast cancer survivors versus female population controls in Germany

ERα upregulates the expression of long non-coding RNA LINC00472 which suppresses the phosphorylation of NF-κB in breast cancer

Adjuvant chemotherapy in lobular carcinoma of the breast: a clinicopathological score identifies high-risk patient with survival benefit

Keynote webinar | Spotlight on antibody–drug conjugates in cancer